Automating Gastroenterology Specialty Drug Prior Auth

Klivira optimizes gastroenterology specialty drug prior auth, accelerating patient access to critical biologics and high-cost therapies while reducing administrative burden.

For revenue cycle directors and prior authorization coordinators in gastroenterology, managing specialty drug PAs presents unique challenges. High-volume biologics for conditions like Inflammatory Bowel Disease (IBD) and Hepatitis C require precise documentation and navigation of complex payer policies. Klivira provides a clear, automated path forward.

The Unique Burden of GI Specialty Drug Prior Authorization

Gastroenterology practices face a significant prior authorization burden, particularly with specialty drugs for chronic conditions. Biologics for Crohn's disease and ulcerative colitis, along with direct-acting antivirals for Hepatitis C, necessitate frequent re-authorizations and meticulous adherence to step therapy protocols. This chronic-treatment cadence, combined with the high cost of these therapies, places immense pressure on administrative teams.

Key Specialty Drug PA Triggers in Gastroenterology

**IBD Biologics:** TNF inhibitors (adalimumab, infliximab), integrin inhibitors (vedolizumab), IL-12/23 inhibitors (ustekinumab, risankizumab), JAK inhibitors (tofacitinib, upadacitinib), and S1P modulators (ozanimod, etrasimod) for Crohn's and UC.
**Hepatitis C Direct-Acting Antivirals (DAAs):** Sofosbuvir-velpatasvir (Epclusa) and glecaprevir-pibrentasvir (Mavyret), with pathways differing based on treatment-naive vs. experienced status.
**Specialty Functional-GI Drugs:** Eluxadoline for IBS-D and prucalopride, linaclotide, and plecanatide for chronic constipation/IBS-C.
**Advanced Imaging:** MRCP, MR enterography, CT enterography for IBD assessment often require PA.

Navigating Medical vs. Pharmacy Benefit for GI Biologics

A core challenge in gastroenterology specialty drug prior auth is the split between medical and pharmacy benefits. Many biologic IBD drugs can be provider-administered (medical benefit) or self-administered (pharmacy benefit), with the same agent potentially shifting benefit sides over time for a single patient. Klivira's platform automates this benefit-side determination, ensuring submissions are routed correctly via NCPDP SCRIPT ePA for pharmacy benefits or X12 278 and Da Vinci PAS for medical benefits, preventing critical misclassifications.

Critical Documentation for GI Specialty Drug Approvals

**IBD Biologics:** Diagnosis confirmation (endoscopic, histologic), disease severity (Mayo score, CDAI), prior conventional-therapy trial, TB and hepatitis screening pre-initiation, and step therapy compliance per ACG/AGA guidelines.
**Hepatitis C DAAs:** Genotype, fibrosis stage (FibroSure, elastography), prior-treatment history, and coinfection status.
**Advanced Imaging:** Clear clinical question, prior imaging history, and documentation of conservative-evaluation workup completion.
**Capsule Endoscopy:** Prior workup including upper GI series or EGD, and indication meeting payer-specific medical necessity criteria.

Klivira's Automated Approach to GI Specialty Drug PA

Klivira's platform is engineered to address the specific complexities of gastroenterology specialty drug prior auth. Our system leverages ACG/AGA-guideline-aware step therapy logic for IBD biologics and automates treatment-status classification from EMR medication history. For Hep C DAAs, Klivira supports the necessary genotype, fibrosis stage, and drug-interaction documentation workflows. This automation extends to periodic re-authorization for chronic IBD treatments and intelligent routing based on medical-vs-pharmacy benefit determination, significantly reducing manual effort and denial rates.

Addressing Common Denial Reasons in GI Prior Auth

**Step Therapy Violations:** Failure to document prior conventional therapy or biosimilar trial before non-TNF or brand biologics.
**Missing Disease Severity:** Inadequate documentation of Mayo score, CDAI, or equivalent severity measures for IBD biologics.
**Screening Gaps:** Incomplete TB or hepatitis screening documentation pre-biologic initiation.
**Treatment-Status Misclassification:** Incorrectly classifying patients as treatment-naive vs. experienced for IBD biologics or Hep C DAAs.
**Fibrosis Stage Documentation Gaps:** For Hep C DAAs, missing or insufficient documentation of fibrosis stage.

Frequently asked questions

How does Klivira handle the medical vs. pharmacy benefit split for GI biologics?

Klivira's policy engine automatically determines the correct benefit side (medical or pharmacy) for each specialty drug based on the specific payer and patient context. It then routes the prior authorization request through the appropriate channel, utilizing NCPDP SCRIPT ePA for pharmacy benefits and X12 278 or Da Vinci PAS for medical benefits.

Can Klivira automate re-authorizations for chronic GI conditions like IBD?

Yes, Klivira's platform includes a robust periodic re-authorization workflow specifically designed for chronic treatments such as IBD biologics. It proactively tracks re-authorization cadences, prompts for updated clinical documentation, and facilitates timely resubmission to maintain continuous patient access to therapy.

How does Klivira ensure compliance with GI clinical guidelines for step therapy?

Klivira integrates ACG and AGA guideline-aware step therapy logic directly into its automation platform. It reads medication history from EMRs via FHIR to verify prior conventional therapy trials and adherence to biologic sequencing requirements, helping to prevent denials related to step therapy non-compliance.

Does Klivira assist with documentation for Hepatitis C DAA prior authorizations?

Absolutely. Klivira's workflow for Hepatitis C DAAs is designed to capture and present critical documentation such as genotype, fibrosis stage, prior-treatment history, and drug-drug interaction reviews. This ensures all necessary clinical details are included in the PA submission, aligning with payer requirements.

What EMR data does Klivira leverage for GI specialty drug PAs?

Klivira integrates with EMRs to extract key clinical data, including medication history (FHIR MedicationRequest), treatment response (FHIR Observation resources), diagnosis confirmation, and disease severity assessments (e.g., Mayo score, CDAI). This data is then used to automatically populate PA forms and support clinical necessity arguments.